UY35419A - Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina - Google Patents
Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridinaInfo
- Publication number
- UY35419A UY35419A UY0001035419A UY35419A UY35419A UY 35419 A UY35419 A UY 35419A UY 0001035419 A UY0001035419 A UY 0001035419A UY 35419 A UY35419 A UY 35419A UY 35419 A UY35419 A UY 35419A
- Authority
- UY
- Uruguay
- Prior art keywords
- kinasa
- pirrolo
- piridine
- cdk9 inhibitors
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
Compuestos de fórmula I: donde R1, R2, R3, y R4 tienen cualquiera de los valores que se definen para ellos en la memoria descriptiva, y sales aceptables farmacéuticamente de los mismos. Los compuestos se pueden usar como agentes en el tratamiento de enfermedades, entre las que se inclyue el cáncer. También se proveen composiciones farmacéuticas que comprenden uno o más compuestos de fórmula I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
INDE07452013 | 2013-03-14 | ||
US201361904842P | 2013-11-15 | 2013-11-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY35419A true UY35419A (es) | 2014-10-31 |
Family
ID=51529934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001035419A UY35419A (es) | 2013-03-14 | 2014-03-13 | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina |
Country Status (4)
Country | Link |
---|---|
US (1) | US9073922B2 (es) |
TW (2) | TW201446763A (es) |
UY (1) | UY35419A (es) |
WO (2) | WO2014139328A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106458974B (zh) * | 2014-03-24 | 2019-07-16 | 广东众生药业股份有限公司 | 作为smo抑制剂的喹啉衍生物 |
TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
ES2881195T3 (es) | 2014-09-26 | 2021-11-29 | Gilead Sciences Inc | Derivados de aminotriazina útiles como compuestos inhibidores de quinasas que se unen a TANK |
BR122019013677B1 (pt) | 2015-06-29 | 2024-01-02 | Astrazeneca Ab | Compostos derivados de amida policíclica como inibidores de cdk9, composição e seus usos |
US10316049B2 (en) | 2015-12-17 | 2019-06-11 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
AU2017250302B2 (en) | 2016-04-15 | 2021-01-21 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
EP3686196B1 (en) * | 2017-09-20 | 2024-06-12 | Hangzhou Innogate Pharma Co., Ltd. | Polycyclic compound acting as ido inhibitor and/or ido-hdac dual inhibitor |
ES2931537T3 (es) | 2017-10-18 | 2022-12-30 | Blueprint Medicines Corp | Pirrolopiridinas sustituidas como inhibidores de la quinasa similar al receptor de activina |
JP2024505328A (ja) | 2020-12-18 | 2024-02-06 | アンフィスタ セラピューティクス リミテッド | 標的化されたタンパク質分解のための新規の二官能性分子 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
ES2214546T3 (es) | 1995-09-15 | 2004-09-16 | PHARMACIA & UPJOHN COMPANY | N-oxidos de aminoariloxazolidinona. |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
IL150388A0 (en) * | 1999-12-24 | 2002-12-01 | Aventis Pharma Ltd | Azaindoles |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
PL1737850T3 (pl) | 2004-04-19 | 2008-02-29 | Symed Labs Ltd | Nowy sposób wytwarzania linezolidu i związków pokrewnych |
EP1768967B1 (en) | 2004-07-20 | 2009-04-22 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
TW200615268A (en) | 2004-08-02 | 2006-05-16 | Osi Pharm Inc | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
EP1804823A4 (en) | 2004-09-29 | 2010-06-09 | Amr Technology Inc | NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
CN101389324A (zh) * | 2005-12-23 | 2009-03-18 | 史密丝克莱恩比彻姆公司 | Aurora激酶的氮杂吲哚抑制剂 |
CL2007002708A1 (es) * | 2006-09-22 | 2008-04-04 | Glaxo Group Ltd | Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros. |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
WO2008049856A2 (en) | 2006-10-25 | 2008-05-02 | Ingenium Pharmaceuticals Gmbh | Methods of treating pain using cdk inhibitors |
AU2007336918A1 (en) | 2006-12-22 | 2008-07-03 | Novartis Ag | Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors |
RU2460725C2 (ru) | 2007-02-15 | 2012-09-10 | Ф. Хоффманн-Ля Рош Аг | Новые 2-аминооксазолины в качестве лигандов taar1 |
AU2008240188A1 (en) | 2007-04-13 | 2008-10-23 | Supergen, Inc. | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |
KR20100105802A (ko) | 2007-04-19 | 2010-09-29 | 콘서트 파마슈티컬즈, 인크. | 중수소화된 모르폴리닐 화합물 |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
EP2209774A1 (en) | 2007-10-02 | 2010-07-28 | Concert Pharmaceuticals Inc. | Pyrimidinedione derivatives |
KR20100090772A (ko) | 2007-10-12 | 2010-08-17 | 인게니움 파르마코이티칼스 게엠베하 | 단백질 키나제 억제제 |
US8410124B2 (en) | 2007-10-18 | 2013-04-02 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
AU2008317375B2 (en) | 2007-10-26 | 2013-02-28 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
GB0804592D0 (en) * | 2008-03-12 | 2008-04-16 | Glaxo Group Ltd | Novel compounds |
CA2728559A1 (en) * | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
CA2734802C (en) | 2008-08-22 | 2016-05-31 | Novartis Ag | Pyrrolopyrimidine compounds as cdk inhibitors |
DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
-
2014
- 2014-03-13 WO PCT/CN2014/000265 patent/WO2014139328A1/en active Application Filing
- 2014-03-13 TW TW103109212A patent/TW201446763A/zh unknown
- 2014-03-13 TW TW103109213A patent/TW201444836A/zh unknown
- 2014-03-13 US US14/207,886 patent/US9073922B2/en active Active
- 2014-03-13 WO PCT/US2014/025740 patent/WO2014151444A1/en active Application Filing
- 2014-03-13 UY UY0001035419A patent/UY35419A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW201444836A (zh) | 2014-12-01 |
WO2014151444A1 (en) | 2014-09-25 |
WO2014139328A1 (en) | 2014-09-18 |
TW201446763A (zh) | 2014-12-16 |
US9073922B2 (en) | 2015-07-07 |
US20140275027A1 (en) | 2014-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39630A (es) | Inhibidores de bromodominios | |
UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina | |
CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
CR20150474A (es) | Inhibidores de bromodominios tetracíclicos | |
CR20160035A (es) | Inhibidores de bromodominios | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
UY37205A (es) | Inhibidores de bromodominios | |
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
CR20170563A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
CO6630162A2 (es) | Derivados del ácido 1-amino -2-ciclopropiletilboronico | |
CR20150045A (es) | Inhibidores de hepatitis c | |
UY33775A (es) | Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos | |
CR20150250A (es) | Nuevos derivados de piridina | |
CR20150447A (es) | Nuevos derivados de pirazol | |
PE20151979A1 (es) | Compuestos quimicos | |
UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
CY1120133T1 (el) | Πυριδαζινονες ως αναστολεις ενζυμου daao | |
CR20180298A (es) | Nuevos derivados de fenilo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20201204 |